Minisimposio “Cancer immunotherapy: crossing the next frontier”
Miércoles, 24 de mayo. CaixaForum. Zaragoza
| 15.45-16.00 | Apertura oficial por autoridades locales | |
| 16.00-17.30 | Sesión 1. Cancer immunotherapy in clinical practice |
|
| Moderador: | Roberto Pazo. Hospital Miguel Servet. Zaragoza | |
| Ponentes: | Current aspectsof the implementation of immunotherapy in clinical practice Emiliano Calvo. Centro Integral Oncológico Clara Campal. Madrid |
|
| The experience of implementing our own proposal of CART19 in Spain Manel Juan. IDIBAPs. Barcelona |
||
| Immunotherapy and Clinical Practice at the Hospitals in Zaragoza Rodrigo Lastra. Hospital Clínico Universitario Lozano Blesa. IACS/IIS.Aragón Ángel Artal. Hospital Clínico Universitario Miguel Servet, IACS/IIS. Aragón |
||
| 17.30-18.00 | Coffee Break | |
| 18.00-19.00 |
Sesión 2 Immunotheraphy beyond checkpoints |
|
| Moderadores: | Alberto Anel. Universidad de Zaragoza Dolores Isla. Hospital Lozano Blesa. Zaragoza |
|
| Ponentes: | From tumor cell metabolism to tumor immune escape Martín Villalba. Institute for Regenerative Medicine and Biotherapy. CHU Montpellier Hôpital Saint-Eloi |
|
| Immunotherapy with oncolytic adenoviruses Ramón Alemany IDIBELL-Bellvitge Biomedical Research Institute |
||
| 19.00-20.00 | Sesión 3 Modulating cancer cell immunogenicity |
|
| Moderadores: | Juanjo Lasarte. CIMA. Pamplona Ignacio Melero. Clínica Universitaria de Navarra. Pamplona |
|
| Ponentes: | Manipulating inflammation to raise cancer immunogenicity Santiago Zelenay. Cancer Research UK Manchester Institute |
|
| Immunological aspects of cancer chemotherapy Lionel Apetoh. Genetic and Immunotherapy Medical Institute. Cancer Centre Georges Francois Leclerc. INSERM 1231. Dijon, France. |
||
| 20.00 | Cierre del Simposio | |
Inscripción Gratuita
PLAZAS BAJO DISPONIBILIDAD
COLABORADORES
AstraZeneca
ARAID
Bristol-Myers Squibb
Conda
Fundación Biomédica Miguel Servet
Grupo Español de Inmunoterapia
IDT
IIS Aragón
Miltenyi Biotec
Obra Social La Caixa
Red de Inmunoterapia del Cáncer
Roche
Universidad de Zaragoza
Waters
